{"F": {"ts_code": "US.GYRE", "name": "Gyre Therapeutics", "mkt": "US", "ccy": "美元", "sw1": "生物技术", "sw2": "生物技术", "sw3": "", "ind": "生物技术", "fin_source": "futu", "market": "NASDAQ", "list_date": "20060412", "is_fin": false, "roles": {"fin": false, "commodity": false, "precious": false, "regulated": false, "hard": false, "growth": true}, "province": null, "main_business": "", "introduction": "", "close": 6.86, "pe_ttm": -32.666, "pb": 6.738, "dv_ttm": 0.0, "total_mv": 72739.16141799999, "trade_date": "20260904", "years": ["最近年报"], "multi_year": false, "period": "最近年报", "gm_series": [95.4], "rev_series": [1.2], "np_series": [0.1], "roe_series": [5.9], "rev_ttm": 1.2, "np_ttm": -0.2, "ocf_ttm": -0.0, "fcf_ttm": null, "fcf_yield": null, "ocf_yield": -0.7, "gm_median": 95.4, "gm_std": null, "gm_stab": null, "gm_chg_2022": null, "npm_median": 8.5, "roe_median": 5.9, "commodity": false, "hard_ratio": 10.9, "fix_assets": 0.2, "hard_note": "PP&E 毛额 × 0.5 近似净额", "goodwill_ratio": null, "pb_calc": null, "capex_dep": null, "interest_debt": null, "debt_ebitda": null, "ebitda": 0.1, "debt_ratio": 14.4, "debt_mv": null, "payout": null, "div_years": 0, "rev_cagr3": null, "np_cagr3": null, "rev_yoy": 10.2, "np_yoy": -44.8, "np_vol": null, "loss_years": 1, "far_share": 100, "earn_yield": null, "consensus_n": 0, "fwd_pe": null, "fwd_pe2": null, "fwd_g1": null, "fwd_g2": null, "peg": null, "consensus_disp": null, "mainbz": [], "ret_prev_year": null, "ret_prev2_year": null, "ret_pivot": null, "prev_year": "", "prev2_year": "", "ret_ytd": -2.8, "ret_20": 2.8, "ret_60": 15.3, "ret_120": -8.5, "ret_250": -13.1, "mdd_250": null, "vol_250": null, "pos_52w": 72.8, "eps": 0.02}, "S": {"duration": 100, "pricing": 80, "hard": 17, "bondness": 13}, "label": "亏损或困境", "tags": [], "text": {"像什么": ["TTM 归母净利 -0.2 亿;PE 为负,估值指标失真。", "资产负债率 14%,有息负债 —,经营现金流/市值 -0.7%:先看现金流能否覆盖利息,再谈久期。"], "为什么(不)算钱的替代品": "只占定价权一条(毛利率 95.4%),硬资产占比 11%。分子能跟上通胀,但没有重置成本对冲;按'定价权·品牌'看,不按硬资产看。", "加息期怎么走": "利率上行对高杠杆亏损企业是再融资压力,不是估值问题;周期底部的反转看行业价格,不看贴现率。", "四问": [["当前 FCF 能覆盖多少市值?", "经营现金流/市值 -0.7%(futu 无资本开支,FCF 按经营现金流 × 0.7 近似)。极低或为负。"], ["能否每年提价而不掉量?", "毛利率最新年报 95.4%。能。"], ["资产重置成本随通胀涨吗?", "固定资产占总资产 11%。没有资产可言。"], ["估值里多少来自 5 年后的故事?", "按 PE 为负 粗算,约 100%(1 − 5/PE)。>70%,把 5 年后的假设砍一半,这个股票值多少钱?"]], "价格行为": "近一年 -13%,现价在 52 周高点的 73%;近 20 / 60 / 120 日 3% / 15% / -8%。", "行业对照": ["同富途行业「生物技术」593 家中位:PE 13.7 / 股息率 0.0% / 毛利率 80.5% / 固定资产占比 5% / 分红率 0%。", "Gyre Therapeutics:PE 比行业中位低 46.4倍;股息率 与行业中位持平;毛利率 比行业中位高 14.9个百分点;固定资产占比 比行业中位高 5.6个百分点。"]}}